Johnson Fistel, PLLP investigates claims on behalf of long-term shareholders of Erasca, Inc. (ERAS), DICK'S Sporting Goods, Inc. (DKS), Corcept Therapeutics Incorporated (CORT), and Charter Communications, Inc. (CHTR). SAN DIEGO, Oct. 09, 2026 (GLOBE NEWSWIRE) - Johnson Fistel, PLLP is investigating potential claims on behalf of current, long-term shareholders of Erasca, Inc. (NASDAQ: ERAS), DICK'S Sporting Goods, Inc. (NYSE: DKS), Corcept Therapeutics Incorporated (NASDAQ: CORT), and Charter Communications, Inc. (NASDAQ: CHTR) against certain of their officers and directors for alleged breaches of fiduciary duty. Shareholders who purchased shares before the dates listed below and have continuously held those shares may have standing to seek corporate governance reforms and the return of funds to the company. For a named plaintiff, the firm may also seek a reasonable incentive award, subject to court approval. Representation is on a contingency-fee basis, with no legal fees or expenses payable by participating shareholders. Erasca, Inc. (NASDAQ: ERAS) If you purchased Erasca shares before January 14, 2025, and have continuously held those shares, you may have standing to seek corporate governance reforms at Erasca, including improvements to clinical-development oversight, intellectual-property risk management, disclosure practices, and executive accountability. To learn more, visit https://www.johnsonfistel.com/investigations/erasca/ or contact Johnson Fistel, PLLP at [email protected] or (619) 814-4471. There is no cost or obligation. Complaint Allegations A previously filed securities complaint concerns Erasca's disclosures about its drug candidate ERAS-0015. According to the complaint, Erasca disclosed on April 27, 2026, that Revolution Medicines had sent a letter raising patent-infringement and trade-secret allegations and challenging public comparisons between ERAS-0015 and Revolution Medicines' RMC-6236. The complaint also addresses subsequent preliminary clinical results, a reported patient death, and Erasca's acknowledgment that comparisons with other drug candidates relied on inherently limited cross-study analyses rather than direct, head-to-head trials. DICK'S Sporting Goods, Inc. (NYSE: DKS) If you purchased DICK'S Sporting Goods shares before May 25, 2022, and have continuously held those shares, you may have standing to seek corporate governance reforms at DICK'S, including improvements to inventory management, demand forecasting, disclosure controls, and executive oversight. To learn more, visit https://www.johnsonfistel.com/investigations/dicks-sporting-goods/ or contact Johnson Fistel, PLLP at [email protected] or (619) 814-4471. There is no cost or obligation. Complaint Allegations A previously filed securities class action complaint alleges that DICK'S and certain executives misrepresented demand and inventory conditions in the Company's outdoor segment. Specifically, demand allegedly weakened more rapidly than disclosed, leaving the Company with excess merchandise. The complaint further alleges that operational improvements promoted by defendants were insufficient to prevent inventory liquidation from reducing profitability. Consequently, defendants' favorable statements about the Company's business and outlook allegedly lacked a reasonable basis. Corcept Therapeutics Incorporated (NASDAQ: CORT) If you purchased Corcept shares before October 31, 2024, and have continuously held those shares, you may have standing to seek corporate governance reforms at Corcept, including improvements to regulatory-risk oversight, clinical-data disclosures, internal controls, and executive accountability. To learn more, visit https://www.johnsonfistel.com/investigations/corcept-therapeutics-inc-2/or contact Johnson Fistel, PLLP at [email protected] or (619) 814-4471. There is no cost or obligation. Complaint Allegations A previously filed securities class action complaint alleges that Corcept and certain executives misled investors about the likelihood of FDA approval of relacorilant for patients with hypercortisolism. Defendants allegedly expressed confidence in the application while failing to disclose repeated FDA concerns about whether the supporting clinical evidence was adequate. On December 31, 2025, Corcept announced that the FDA had issued a Complete Response Letter requiring additional evidence of effectiveness before it could reach a favorable benefit-risk assessment. The complaint alleges that this disclosure revealed previously undisclosed regulatory risks. Charter Communications, Inc. (NASDAQ: CHTR) If you purchased Charter shares before July 26, 2024, and have continuously held those shares, you may have standing to seek corporate governance reforms at Charter, including improvements to subscriber-trend reporting, financial forecasting, disclosure controls, and executive oversight. To learn more, visit https://www.johnsonfistel.com/investigations/charter-communications-inc-nasdaq-chtr/ or contact Johnson Fistel, PLLP at [email protected] or (619) 814-4471. There is no cost or obligation. Complaint Allegations A previously filed securities class action complaint alleges that Charter and certain executives misled investors about the business consequences of the termination of the Federal Communications Commission's Affordable Connectivity Program ("ACP"). According to the complaint, defendants understated the resulting pressure on Internet subscriber trends, revenue, and sustainable earnings growth. The complaint further alleges that these conditions undermined the basis for defendants' optimistic statements about operations and long-term EBITDA growth, with subsequent disappointing results allegedly exposing the earlier misrepresentations. About Johnson Fistel, PLLP | Top Law Firm, Securities Fraud, Investors Rights: Johnson Fistel, PLLP is a nationally recognized shareholder rights law firm with offices in California, New York, Georgia, Idaho, and Colorado. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. We also extend our services to foreign investors who have purchased on U.S. exchanges. For more information about the firm and how we may be able to help you recover your losses, please visit https://www.johnsonfistel.com. Achievements: In 2024, Johnson Fistel was ranked in the Top 10 Plaintiff Law Firms by ISS Securities Class Action Services. The firm has recovered approximately $90,725,000 for aggrieved clients in cases where it served as lead or co-lead counsel, marking the eighth time it has been recognized among the top U.S. plaintiffs' securities law firms. Johnson Fistel, PLLP 501 W. Broadway, Suite 800 San Diego, CA 92101 James Baker, Investor Relations, or Frank J. Johnson, Esq. (619) 814-4471 [email protected] or [email protected]

Erasca, Inc. (NASDAQ:ERAS) stock has consensus target price of $22.09. October 3, 2026 Key points. * Analysts maintain a "Moderate Buy" consensus on Erasca, with eight buy, two hold, and one sell rating among 11 brokerages. The average 12-month price target is $22.09, above the stock's reported $14.74 opening price. * Erasca shares were up 1.1%, with a market capitalization of approximately $5.16 billion and a 52-week range of $2.11 to $24.28. The company reported quarterly EPS of negative $0.14, missing the consensus estimate of negative $0.11. * Institutional investors and hedge funds own approximately 67.78% of Erasca's stock. The clinical-stage biopharmaceutical company is developing precision cancer medicines targeting abnormalities in the RAS/MAPK signaling pathway. * Five stocks to consider instead of Erasca. Erasca, Inc. (NASDAQ:ERAS - Get Free Report) has received an average recommendation of "Moderate Buy" from the eleven brokerages that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating and eight have given a buy rating to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $22.09. A number of analysts have weighed in on ERAS shares. HC Wainwright increased their price target on Erasca from $18.00 to $22.00 and gave the stock a "buy" rating in a report on Wednesday, August 12th. Bank of America lifted their target price on Erasca from $18.00 to $20.00 and gave the stock a "neutral" rating in a report on Friday, August 14th. Morgan Stanley lifted their price objective on shares of Erasca from $12.00 to $21.00 and gave the company an "equal weight" rating in a research note on Monday, July 20th. Guggenheim increased their target price on shares of Erasca from $20.00 to $21.00 and gave the stock a "buy" rating in a research note on Thursday, August 13th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Erasca in a report on Tuesday, September 8th. Erasca stock up 1.1%. Shares of Erasca stock opened at $14.74 on Friday. The stock has a market cap of $5.16 billion, a price-to-earnings ratio of -15.52 and a beta of 0.61. Erasca has a twelve month low of $2.11 and a twelve month high of $24.28. The company's fifty day moving average is $16.85 and its 200 day moving average is $15.87. Erasca (NASDAQ:ERAS - Get Free Report) last announced its earnings results on Tuesday, August 11th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.03). As a group, equities analysts anticipate that Erasca will post -0.49 earnings per share for the current fiscal year. Institutional inflows and outflows. A number of institutional investors have recently added to or reduced their stakes in the company. Wealthcare Advisory Partners LLC raised its holdings in Erasca by 5.0% during the second quarter. Wealthcare Advisory Partners LLC now owns 15,924 shares of the company's stock worth $292,000 after buying an additional 756 shares during the last quarter. Abel Hall LLC grew its holdings in shares of Erasca by 8.1% during the first quarter. Abel Hall LLC now owns 16,947 shares of the company's stock valued at $274,000 after buying an additional 1,265 shares during the last quarter. Nykredit A S bought a new stake in shares of Erasca during the second quarter worth about $29,000. Allworth Financial LP acquired a new stake in shares of Erasca in the 2nd quarter worth about $34,000. Finally, EverSource Wealth Advisors LLC lifted its position in Erasca by 77.8% in the 1st quarter. EverSource Wealth Advisors LLC now owns 4,249 shares of the company's stock valued at $69,000 after acquiring an additional 1,859 shares in the last quarter. 67.78% of the stock is owned by institutional investors and hedge funds. Erasca company profile. Erasca, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for cancers driven by abnormal signaling in the RAS/MAPK pathway. The company's research and development activities target tumors with RAS mutations or other alterations that can promote cancer growth and resistance to treatment. Discover more All Access membership Stock research tools Erasca's pipeline has included naporafenib, an investigational pan-RAF inhibitor designed to block signaling downstream of RAF proteins, as well as other targeted therapies aimed at genetically defined cancer populations. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Erasca, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Erasca wasn't on the list. While Erasca currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you'll find 7 stocks that could play a major role in the next tech-driven market boom. Continue following MarketBeat